Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review
Clinical Scorecard: Tagraxofusp for Adult Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Review of Clinical Trials and Real-World Evidence
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | CD123-directed cytotoxin targeting high-level expression of CD123. |
| Target Population | |
| Care Setting | |
Key Highlights
- Overall response rates (ORR) of 71%-90% in frontline trials.
- Complete response (CR/CRc) rates of 56%-72%.
- Real-world cohorts showed ORR of 65%-90%.
- Capillary leak syndrome (CLS) identified as a defining toxicity.
- Long-term survival influenced by successful bridging to allogeneic HSCT.
Guideline-Based Recommendations
Diagnosis
- Histologically confirm BPDCN in adults.
Management
- Use tagraxofusp as monotherapy or in combination regimens.
Monitoring & Follow-up
- Monitor for capillary leak syndrome and hepatotoxicity.
Risks
- Variable incidence of CLS across clinical trials and observational cohorts.
Patient & Prescribing Data
Adults (≥18 years) with BPDCN.
Tagraxofusp shows consistent remission-inducing activity across treatment settings.
Clinical Best Practices
Related Resources & Content
